Fulcrum Therapeutics (FULC) Interest & Investment Income (2018 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Interest & Investment Income of -$54000.0 for Q2 2026, down 550.0% year-over-year from $12000.0 in Q2 2025, and up 92.14% quarter-over-quarter from -$687000.0 in Q1 2026.
Powered by 
Analysis
Fulcrum Therapeutics (FULC) Interest & Investment Income (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Interest & Investment Income for 7 consecutive years, with -$54000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Interest & Investment Income fell 550.0% year-over-year to -$54000.0; the TTM figure through Jun 2026 stood at -$649000.0 (down 244.87% YoY), while the FY2025 annual figure was $44000.0, down 83.46% from the prior year.
- Interest & Investment Income climbed to -$54000.0 in Q2 2026 per FULC's latest filing, from -$687000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $745000.0 in Q3 2024 and bottomed at -$693000.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged -$107500.0 across 5 years, with a median of -$57000.0 in 2025.
- On a YoY basis, Interest & Investment Income climbed as much as 540.0% in 2022 and fell as far as 34550.0% in 2022.
- Fulcrum Therapeutics' Interest & Investment Income stood at $22000.0 in 2022, then sank by 2595.45% to -$549000.0 in 2023, then surged by 54.64% to -$249000.0 in 2024, then jumped by 73.09% to -$67000.0 in 2025, then rose by 19.4% to -$54000.0 in 2026.
- Business Quant data shows FULC's Interest & Investment Income at -$54000.0 in Q2 2026, -$687000.0 in Q1 2026, and -$67000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Fulcrum Therapeutics | 293.24 Mn | 293.24 Mn | - | 3.13 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.13 Mn |
| Mar 31, 2026 | -687,000.00 |
| Dec 31, 2025 | 2.36 Mn |
| Sep 30, 2025 | 2.26 Mn |
| Jun 30, 2025 | 2.52 Mn |
| Mar 31, 2025 | -60,000.00 |
| Dec 31, 2024 | 2.86 Mn |
| Sep 30, 2024 | 3.43 Mn |
| Jun 30, 2024 | 68,000.00 |
| Mar 31, 2024 | -298,000.00 |
| Dec 31, 2023 | 3.24 Mn |
| Sep 30, 2023 | 3.42 Mn |
| Jun 30, 2023 | -549,000.00 |
| Mar 31, 2023 | 146,000.00 |
| Dec 31, 2022 | 1.84 Mn |
| Sep 30, 2022 | 617,000.00 |
| Jun 30, 2022 | 22,000.00 |
| Mar 31, 2022 | -693,000.00 |
| Dec 31, 2021 | -527,000.00 |
| Sep 30, 2021 | 54,000.00 |